measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 H1 investor presentation (available atwww.takeda.com/investors).

Medical information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Please refer to slide 7 of Takeda’s FY2025 H1 investor presentation (available at https://www.takeda.com/investors
=*=*=*=*=*=
当前为第18/19页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页